Marty Makary: “There's about 76 [biosimilars] that the FDA has approved…”

“The good news is there are low cost alternatives. Unfortunately, there are far fewer on the market than should be because of regulatory red tape hurdles. There's about 76 [biosimilars] that the FDA has approved since we started approving biosimilars. Think of biosimilars as the generic version of the expense of biologics. We have 76 that we've approved in 10 years. Probably should have been 200 or 300.” (12:01–12:08)

This is an excerpt from a raw transcript. The assertions have not been audited or verified. Tap the video to view the source footage and understand the context.